ArabicCatalanChinese (Simplified)EnglishFrenchGermanHebrewHindiItalianJapaneseKoreanPortugueseRussianSpanishYiddish
Showing posts with label Vaccination. Show all posts
Showing posts with label Vaccination. Show all posts

12 March, 2016

Changing oral vaccine to inactivated polio vaccine might increase mortality

None - This image is in the public domain and ...None - This image is in the public domain and thus free of any copyright restrictions. As a matter of courtesy we request that the content provider be credited and notified in any public or private usage of this image. (Photo credit: Wikipedia)
We, the undersigned, write as physicians and scientists committed to optimising the beneficial effects of vaccines to reduce infant mortality worldwide. In settings with high childhood mortality, live vaccines such as oral polio vaccine (OPV), BCG vaccine, and measles vaccine might have heterologous (non-specific) effects that reduce mortality from diseases other than poliomyelitis, tuberculosis, and measles, respectively, whereas inactivated vaccines might increase all-cause mortality.1 The importance of these effects is controversial.
See full Article here.

14 February, 2014

Lower inmune response to vaccination when are manufacturaded with perfluoritaned compunds

Vaccination (Photo credit: Sanofi Pasteur)
A new study finds that perfluorinated compounds (PFCs), widely used in manufactured products such as non-stick cookware, waterproof clothing, and fast-food packaging, were associated with lowered immune response to vaccinations in children. It is the first study to document how PFCs, which can be transferred to children prenatally (via the mother) and postnatally from exposure in the environment, can adversely affect vaccine response.
The study appears in the January 25, 2012 issue of the Journal of the American Medical Association (JAMA). Read a background memo on the findings.
“Routine childhood immunizations are a mainstay of modern disease prevention. The negative impact on childhood vaccinations from PFCs should be viewed as a potential threat to public health,” said study lead author Philippe Grandjean, adjunct professor of environmental health at Harvard School of Public Health.
PFCs have thousands of industrial and manufacturing uses. Most Americans have the chemical compounds in their bodies. Prior studies have shown that PFC concentrations in mice similar to those found in people suppressed immune response, but the adverse effects on people had been poorly documented.
The researchers analyzed data on children recruited at birth at National Hospital in Torshavn, Faroe Islands during 1999-2001. A total of 587 participated in follow-up examinations. Children were tested for immune response to tetanus and diphtheria vaccinations at ages 5 and 7 years. PFCs were measured in maternal pregnancy serum and in the serum of children at age 5 to determine prenatal and postnatal exposure.
The results showed that PFC exposure was associated with lower antibody responses to immunizations and an increased risk of antibody levels in children lower than those needed to provide long-term protection. (Antibody concentrations in serum are a good indicator of overall immune functions in children.) A two-fold greater concentration of three major PFCs was associated with a 49% lower level of serum antibodies in children at age 7 years.
“We were surprised by the steep negative associations, which suggest that PFCs may be more toxic to the immune system than current dioxin exposures,” said Grandjean.
The PFC concentrations are similar to or slightly below those reported in U.S. women, and most serum PFC levels in Faroese children at age 5 were lower than those measured in U.S. children aged 3 to 5 years in 2001-2002.
This study was supported by the National Institute of Environmental Health Sciences (part of the National Institutes of Health), the U.S. Environmental Protection Agency, the Danish Council for Strategic Research, and the Danish Environmental Protection Agency.
“Serum Vaccine Antibody Concentrations in Children Exposed to Perfluorinated Compounds,” Philippe Grandjean, Elisabeth Wreford Andersen, Esben Budtz-Jorgensen, Flemming Nielsen, Kare Molbak, Pal Weihe, Carsten Heilmann, JAMA, January 25, 2012, Vol. 307, No. 4, pp. 391-397
Visit the HSPH website for the latest news, press releases and multimedia offerings.
For more information:
Todd Datz

04 February, 2014

USA: Recommended Immunization Schedule for Persons Age 0 Through 18 Years

Morning Calm Weekly Newspaper - Korea Region -...
Morning Calm Weekly Newspaper - Korea Region - US Army Korea - IMCOM - November 6, 2009 (Photo credit: U.S. Army Korea (Historical Image Archive))

Source: CDC

United States, 2014

Print PDF document of this schedule

These recommendations must be read with the footnotes that follow. For those who fall behind or start late, provide catch-up vaccination at the earliest opportunity as indicated by the green bars in tables below. To determine minimum intervals between doses, see the catch-up schedule. School entry and adolescent vaccine age groups are 4-6 yrs and 11-12 yrs.

17 June, 2013

Citing Side Effects, Japan Pulls Recommendations For HPV Vaccines

vaccinationPharmalot by  

In the latest blow to drugmakers that market HPV vaccines, the Japanese health ministry has withdrawn its recommendation for vaccination after receiving hundreds of side effects reports of long-term pain and numbness, among other things, The Asahi Shimbun writes. Although vaccines will remain available, local health officials are being told not to promote vaccination while studies are conducted.
“The decision does not mean that the vaccine, itself, is problematic from the view of safety, “ Mariko Momoi, vp of the International University of Health and Welfare, who headed a task force probing the issue, tells the paper. “By implementing investigations, we want to offer information that can make the people feel more at ease.”
To date, an estimated 3.28 million people have been vaccinated, and 1,968 cases of possible side effects, including body pain, have been reported and the task force examined 43 cases, the paper writes. However, a causal relationship between vaccination and pain and numbness could not be established, which prompted the decision to run further studies by the ministry.
We asked Merck, which sells Gardasil, and GlaxoSmithKline, which sells Cervarix, for comment and will update you accordingly.
The move comes amid lingering concern over HPV vaccines. Earlier this year, the journal Pediatrics published a study, which analyzed US vaccination data for teens between the ages of 13 and 17 between 2008 and 2010, and  found a growing number of parents believe the shots are unnecessary and continue to worry about reports of side effects.
Specifically, 40 percent of parents surveyed five years earlier reported they would not vaccinate their girls against the human papillomarivus, which can lead to cervical cancer. In 2009, that rose to 41 percent and then climbed to 44 percent in 2010. And parents concerned about side effects rose from 5 percent in 2008 to 16 percent in 2010 (back story).
As noted previously, the survey results - and now the decision by the Japanese health ministry – underscore that drugmakers and public health officials have more work to do to convince parents the vaccines are safe, even though vaccination is recommended by public health officials, such as the Worth Health Organization to thwart cervical cancer.
“We welcome the decision not to recommend the vaccination even though it is a small step,” Mika Matsufuji, head of a group of parents who say their children have suffered side effects from the vaccination, tells the paper. “Parents can decide whether their children should receive the vaccination or not.”
Vaccination, you may recall, has been controversial for other reasons, as well. In the US, where some parents and social conservatives continue to express concerns that HPV vaccines can be seen as a green light for teenage girls to engage in promiscuous sex, even though another recent study suggested that is not the case (back stories here, here and here).
In the US, Gardasil was initially approved for females between the ages of 9 to 26, and approval was expanded in 2009 to boys and men for preventing genital warts caused by certain types of HPV. GlaxoSmithKline’s Cervarix is approved for preventing HPV in females ages 9 through 25.
As we reported earlier this year, despite ongoing hurdles and controversy, Merck (MRK) has turned Gardasil into a big seller. Last year, the vaccine generated $1.6 billion in revenue, a 35 percent jump from the previous year and up 65 percent from 2010, the first full year in which Gardasil was marketed toward boys and men (see page 4). Glaxo (GSK), however, has not fared as well with Cervarix. Sales for its HPV vaccine declined 46 percent to about $408 million (see page 19).

Enhanced by Zemanta


Related Posts Plugin for WordPress, Blogger...